As we count down the months to the pivotal Phase 3 readout, our conviction grows stronger that Diamyd® may become the first precision immunotherapy approved for Type 1 Diabetes.
10-20% of the more than 537 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.
The antigen-specific immunotherapy Diamyd® is a disease-modifying investigational medicine in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.
The efficacy of intralymphatic administration of Diamyd® on preserving the insulin producing ability in Type 1 Diabetes is being confirmed in the precision medicine Phase III trial DIAGNODE-3. Diamyd® is also being evaluated in the prevention Phase II trial DiaPrecise.